Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    An NIH notice about its terminology transition appears above the 403 error page. The site revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T20:43:22.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-06T20:54:04.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The Study Record page now displays a 403 Forbidden error, and the error page includes a minimal header and a Home link, indicating that access to the record is blocked.
    Difference
    19%
    Check dated 2026-09-22T23:09:40.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The page's Revision tag was updated from v3.6.6 to v3.7.0, indicating an updated version in the site metadata.
    Difference
    0.1%
    Check dated 2026-09-15T21:44:51.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.5 to v3.6.6. This reflects a minor update to the page's revision metadata rather than substantive content changes.
    Difference
    0.1%
    Check dated 2026-09-01T17:51:11.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.4 to v3.6.5. This indicates a new version of the site.
    Difference
    0.0%
    Check dated 2026-08-11T18:00:05.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.